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Portal-systemic collaterals and hepatic encephalopathyChronic liver diseases or liver injuries commonly result in
portal hypertension and the formation of portal-to-systemic
collaterals (PSCs).1 PSCs form through the appearance of
large or small vascular communications between the portal
and systemic circulatory routes. These collateral vasculatures
will shunt part of the portal blood flow, bypassing the liver, to
the systemic circulation. Shunting the portal blood flow
through collateral vessels is an attempt to decompress a highly
pressurized portal system. However, the shunting of portal
blood flow through PSCs may interfere with the detoxification
processes of the liver. The uncleared toxic substances in
the bloodstream may then reach the brain to cause neuro-
psychological dysfunction, known as hepatic encephalopathy.
Hepatic encephalopathy is an important complication
occurring in severe acute or chronic liver injury. At present, the
pathophysiology of hepatic encephalopathy is not completely
understood. Recent evidence has shown that hepatic encepha-
lopathy is a multifactorial and complex disease involving the
imbalanced production, metabolism and regulation of various
neurotoxins and neurotransmitters.2 However, it is generally
accepted that ammonia is a key molecule, playing an important
role in the pathogenesis of hepatic encephalopathy. Under
normal conditions, the ammonia generated by enterocytes and
bacteria in the colon will be transported by the portal vein to
hepatocytes for detoxification. However, in the injured liver,
hyperammonemia may occur, either through the overproduction
of ammonia in the intestine or due to a reduction in the meta-
bolic capacity of the liver’s urea cycle. The clearance of
ammonia may be compromised further by the presence of
portal-systemic shunting. Therefore, understanding the role
of PSCs in the pathophysiology of hepatic encephalopathy is
a practical and important issue.
The Working Group on Hepatic Encephalopathy has pub-
lished the classification of hepatic encephalopathy according
to its clinical presentation and etiology.3,4 Hepatic encepha-
lopathy can be divided into three categories: Type A, acute
liver failure; Type B, a portal-systemic bypass without
intrinsic liver disease; and Type C, cirrhosis with portal
hypertension and/or a portal-systemic shunt. Type C can be
further divided into three patterns, the episodic, persistent, and
minimal hepatic encephalopathy, depending on the clinical
presentation of the patient. Patients suffering from episodic
hepatic encephalopathy may have seemingly normal cognitive
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doi:10 1016/j.jcma.2011.10.012functioning between episodes. Patients with persistent hepatic
encephalopathy never become completely free of hepatic
encephalopathy. Patients with minimal hepatic encephalop-
athy remain clinically undetectable.
Portal-systemic shunting is the major cause in patients with
Type B hepatic encephalopathy. This type of encephalopathy
was first described as “portal-systemic encephalopathy” by
Raskin et al in 1964.5 The main feature of these patients is that
liver injury and portal hypertension may be slight or absent in
them. For this reason, patients with Type B hepatic encepha-
lopathy are frequently misdiagnosed as having psychiatric
disorders such as dementia, depression and others. The actual
cause of the formation of PSCs in these patients remains
unclear; possible etiologies include congenital abnormalities
and degenerative changes, or they may be secondary to inva-
sive procedures or trauma. Based on the location of shunting,
either inside or outside the liver, Watanabe et al classified this
disease into five types and suggested appropriate treatments.6
It is worth noting that portal-systemic encephalopathy has
been increasingly reported in the literature in recent years.7e10
It is crucial to have an appropriate animal model to study
the pathophysiology of hepatic encephalopathy and to test
potential therapies.11 Although there are several animal
models for the study of liver disease, a satisfactory animal
model of hepatic encephalopathy is still lacking. Portacaval
anastomosis (PCA) in rats is the most used animal model in
the study of chronic hepatic encephalopathy. An end-to-side
PCA creates 100% portal-to-systemic shunting but, however,
it lacks hepatocellular injury. The hyperammonemia model is
created by feeding animals with an ammonium acetate-
supplemented diet, with urea or by an injection of ammo-
nium. It is a useful model to study the toxic effect of ammonia
and related metabolic changes, but there is no liver injury or
portal-systemic shunting in this model. The chronic liver-
injured model of hepatic encephalopathy can be induced by
common bile duct ligation (CBDL). In this model, the amount
of portal-systemic shunting develops gradually but varies
widely from less than 30% up to 60%. Though CBDL rats may
not develop overt hepatic encephalopathy, their ammonia
levels are increased and their motor activities are decreased.
Thioacetamide-induced fulminant hepatic failure has also
been used in the study of hepatic encephalopathy.12 In addition
to severe liver injury, this model presents with neurologicalhinese Medical Association. All rights reserved.
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systemic shunting. Recently, the partial portal vein ligation
(PVL) model was used to investigate the role of PSCs in the
development of hepatic encephalopathy by Hsin et al.13 In
the PVL model, liver function is completely normal and the
degree of portal-systemic shunting is usually greater than
90%. The PVL model is similar to the PCA model, with only
small differences in the degree of portal-systemic shunting.
These two animal models represent models of Type B hepatic
encephalopathy.
The study of Hsin et al found that high-degree portal-
systemic shunting without significant liver damage in PVL rats
may not be adequate for the development of hepatic encepha-
lopathy.13 This observation is not fully consistent with the
clinical presentations of patients with Type B hepatic enceph-
alopathy. It is possible that the neuropsychiatric presentations
of Type B hepatic encephalopathy cannot be reproduced in the
PVL model or are undetectable by current methodology.
Moreover, the measurement of motor activities may not be
sensitive enough to detect the subtle neuropsychiatric changes
in Type B hepatic encephalopathy. In contrast, Hsin et al found
that there was a significant correlation between the degree of
portal-systemic shunting and the changes of motor activities
in CBDL rats (a model of Type C hepatic encephalopathy).
Thus, it is reasonable to say that liver function impairment is
more critical for the development of hepatic encephalopathy
when compared with PSCs. However, when liver dysfunction
is not significant, the PSCs themselves may become the
major cause of Type B hepatic encephalopathy, delaying the
clearance of circulating neurotoxins and precipitating or
sustaining neuropsychiatric dysfunction. The relationship
among hepatic detoxification ability, neurotoxins and the
degree of portal-systemic shunting in the pathophysiology of
portal-systemic encephalopathy deserves further investiga-
tion in future study.
Currently, there is no good model of hepatic encephalopathy
suitable for all purposes of studies. The ideal animal model of
hepatic encephalopathy should have chronic liver injury, PSCs,
wide-range presentation of hepatic encephalopathy from
subclinical to deep coma, precipitation factors and characteristic
brain changes.11 With this ideal model, the interplay between
PSCs and other neurotoxic factors and the complex pathogen-
esis of hepatic encephalopathy may be gradually revealed.
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